Early evidence for the potential efficacy of this route was published in 1999, where 18 patients with B12 deficiency treated exclusively with 712 days of 2 mg of sublingual cobalamin daily had 4 times higher B12 levels compared to pre-treatment, reaching therapeutic ranges ( There have also been further studies comparing treatment outcomes from the sublingual route to the more established IM and oral routes
ULRR, upper limit of the reference range causes acute hepatitis, but only hepatitis B, C, and D viruses cause chronic hepatitis, although chronic hepatitis E can develop in the context of immunosuppression
Overall, BPC-157 has been suggested in various studies to potentially help with healing joint, tendon, and muscle tissue, as well as nerve tissue
Physical therapy, sleep, nutrition, stress management, and good rehab are the foundation of recovery and pain management
Injectable use should only be handled by qualified medical professionals in a clinical setting
